Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 7, 2026 | $12.23 | −4.5% | $4.29B | +16.7% | $10.88 |
| Q1 FY26ended Mar 31, 2026 | May 5, 2026 | $6.75 | −7.2% | $3.61B | +19.0% | $9.10 |
| Q4 FY25ended Dec 31, 2025 | — | $7.86 | −2.6% | $3.88B | +2.5% | — |
| Q3 FY25ended Sep 30, 2025 | — | $13.62 | +18.0% | $3.75B | +0.9% | — |
| Q2 FY25ended Jun 30, 2025 | — | $12.81 | +3.2% | $3.68B | +3.6% | — |
| Q1 FY25ended Mar 31, 2025 | — | $7.27 | +15.9% | $3.03B | −3.7% | — |
| Q4 FY24ended Dec 31, 2024 | — | $8.07 | −21.0% | $3.79B | +10.3% | — |
| Q3 FY24ended Sep 30, 2024 | — | $11.54 | +29.8% | $3.72B | +10.6% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Regeneron Pharmaceuticals shares, not any token. As of Aug 7, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $12.41 | — | $3.55B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $6.27 | — | $3.15B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $10.22 | — | $3.43B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $8.89 | — | $3.36B | — | — |